-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 O9UYNMaMCVgRhkrdhoTrQe4O11T1SHHonRk3vpcEJMTp7KI16lFN5kmyY/Khwy9t
 8aTWeKeaQG4QHjvQKcTpFA==

<SEC-DOCUMENT>0001104659-07-048482.txt : 20070619
<SEC-HEADER>0001104659-07-048482.hdr.sgml : 20070619
<ACCEPTANCE-DATETIME>20070619130626
ACCESSION NUMBER:		0001104659-07-048482
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070615
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070619
DATE AS OF CHANGE:		20070619

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RETRACTABLE TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0000946563
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				752599762
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16465
		FILM NUMBER:		07928157

	BUSINESS ADDRESS:	
		STREET 1:		511 LOBO LANE
		CITY:			LITTLE ELM
		STATE:			TX
		ZIP:			75068-0009
		BUSINESS PHONE:		9722941010

	MAIL ADDRESS:	
		STREET 1:		511 LOBO LANE
		CITY:			LITTLE ELM
		STATE:			TX
		ZIP:			75068-0009
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a07-16947_18k.htm
<DESCRIPTION>CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div>

<div style="border:none;border-bottom:double windowtext 6.0pt;padding:0in 0in 0in 0in;">

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNITED STATES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM 8-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.42%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event
  reported)</font></p>
  </td>
  <td width="46%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.08%;">
  <p align="left" style="margin:0in 0in .0001pt 40.0pt;text-align:left;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June 15,
  2007</font></p>
  </td>
  <td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.5%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="100%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Retractable Technologies, Inc.</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="22%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.5%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Texas</font></p>
  </td>
  <td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.52%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="11%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="20%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.18%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">000-30885</font></p>
  </td>
  <td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="10%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.74%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="21%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75-2599762</font></p>
  </td>
 </tr>
 <tr>
  <td width="22%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:22.5%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction</font></p>
  </td>
  <td width="11%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:11.52%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="11%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:11.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="20%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:20.18%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission</font></p>
  </td>
  <td width="2%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="10%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:10.74%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="21%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:21.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>
  </td>
 </tr>
 <tr>
  <td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.5%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of incorporation)</font></p>
  </td>
  <td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.52%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.18%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">File Number)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.74%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>
  </td>
 </tr>
 <tr>
  <td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.5%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.52%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:31.98%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.5%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.52%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:31.98%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="66%" colspan="4" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:66.02%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">511 Lobo Lane, Little Elm, Texas</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:31.98%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75068-0009</font></p>
  </td>
 </tr>
 <tr>
  <td width="66%" colspan="4" valign="top" style="border:none;padding:0in 0in 0in 0in;width:66.02%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>
  </td>
  <td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:31.98%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p><p style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p><p style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="283" valign="top" style="padding:0in 0in 0in 0in;width:2.95in;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code</font></p>
  </td>
  <td width="437" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:4.55in;">
  <p align="left" style="margin:0in 0in .0001pt 20.0pt;text-align:left;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(972) 294-1010</font></p>
  </td>
 </tr>
</table>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="100%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former name or former address, if changed since last report)</font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<u>see</u> General Instruction A.2. below):</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&#160;&#160; ] Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&#160;&#160; ] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&#160;&#160; ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&#160;&#160; ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\maruna\07-16947-1\task2199122\16947-1-ba.htm',USER='105282',CD='Jun 19 21:29 2007' -->



<br clear="all" style="page-break-before:always;">
<div>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="13%" valign="top" style="padding:0in .7pt 0in .7pt;width:13.26%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01</font></b></p>
  </td>
  <td width="86%" valign="top" style="padding:0in .7pt 0in .7pt;width:86.74%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Other Events.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="13%" valign="top" style="padding:0in .7pt 0in .7pt;width:13.26%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in .7pt 0in .7pt;width:86.74%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:100.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
  June 15, 2007, Retractable Technologies, Inc. filed a complaint against
  Becton Dickinson and Company (&#147;BD&#148;) in the United States District Court for
  the Eastern District of Texas, Marshall Division.</font></p>
  </td>
 </tr>
 <tr>
  <td width="13%" valign="top" style="padding:0in .7pt 0in .7pt;width:13.26%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in .7pt 0in .7pt;width:86.74%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="13%" valign="top" style="padding:0in .7pt 0in .7pt;width:13.26%;">
  <h5 align="left" style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Item 9.01</font></b></h5>
  </td>
  <td width="86%" valign="top" style="padding:0in .7pt 0in .7pt;width:86.74%;">
  <h5 align="left" style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial Statements and Exhibits.</font></b></h5>
  </td>
 </tr>
 <tr>
  <td width="13%" valign="top" style="padding:0in .7pt 0in .7pt;width:13.26%;">
  <h5 align="left" style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></h5>
  </td>
  <td width="86%" valign="top" style="padding:0in .7pt 0in .7pt;width:86.74%;">
  <h5 align="left" style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></h5>
  </td>
 </tr>
 <tr>
  <td width="13%" valign="top" style="padding:0in .7pt 0in .7pt;width:13.26%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in .7pt 0in .7pt;width:86.74%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibits</font></p>
  </td>
 </tr>
 <tr>
  <td width="13%" valign="top" style="padding:0in .7pt 0in .7pt;width:13.26%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in .7pt 0in .7pt;width:86.74%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="13%" valign="top" style="padding:0in .7pt 0in .7pt;width:13.26%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in .7pt 0in .7pt;width:86.74%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Complaint filed in Civil Action No. 2:07-cv-250 by Retractable
  Technologies, Inc. against BD without exhibits (United States patent nos.
  5,578,011; 5,632,733; and 6,090,077 available at the United States Patent and
  Trademark Office website)</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt 1.0in;text-align:justify;text-indent:-1.0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105442\07-16947-1\task2199075\16947-1-bc.htm',USER='105442',CD='Jun 19 21:18 2007' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURES</font></b></h5>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></h5>

<p style="margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="366" valign="top" style="padding:0in 0in 0in 0in;width:274.5pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DATE:&nbsp;&nbsp;&nbsp;June 19, 2007</font></p>
  </td>
  <td width="245" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:2.55in;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RETRACTABLE TECHNOLOGIES, INC.</font></p>
  </td>
  <td width="109" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:81.9pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="366" valign="top" style="padding:0in 0in 0in 0in;width:274.5pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="245" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:2.55in;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant)</font></p>
  </td>
  <td width="109" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:81.9pt;">
  <p align="left" style="margin:0in 0in .0001pt 60.0pt;text-align:left;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="366" valign="top" style="padding:0in 0in 0in 0in;width:274.5pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="245" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:2.55in;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="109" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:81.9pt;">
  <p align="left" style="margin:0in 0in .0001pt 60.0pt;text-align:left;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="366" valign="top" style="padding:0in 0in 0in 0in;width:274.5pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="55" valign="bottom" style="padding:0in 0in 0in 0in;width:41.4pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="299" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:224.1pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="366" valign="top" style="padding:0in 0in 0in 0in;width:274.5pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="55" valign="bottom" style="padding:0in 0in 0in 0in;width:41.4pt;">
  <p align="left" style="margin:0in 0in .0001pt 30.0pt;text-align:left;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BY:</font></p>
  </td>
  <td width="216" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.25in;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;/s/ THOMAS J. SHAW</font></p>
  </td>
  <td width="83" valign="top" style="padding:0in 0in 0in 0in;width:62.1pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="366" valign="top" style="padding:0in 0in 0in 0in;width:274.5pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="55" valign="bottom" style="padding:0in 0in 0in 0in;width:41.4pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="299" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:224.1pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THOMAS J. SHAW</font></p>
  </td>
 </tr>
 <tr>
  <td width="366" valign="top" style="padding:0in 0in 0in 0in;width:274.5pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="55" valign="bottom" style="padding:0in 0in 0in 0in;width:41.4pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="299" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:224.1pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PRESIDENT AND CHIEF EXECUTIVE</font></p>
  </td>
 </tr>
 <tr>
  <td width="366" valign="top" style="padding:0in 0in 0in 0in;width:274.5pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="55" valign="bottom" style="padding:0in 0in 0in 0in;width:41.4pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="299" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:224.1pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OFFICER</font></p>
  </td>
 </tr>
 <tr height="0">
  <td width="366" style="border:none;"></td>
  <td width="55" style="border:none;"></td>
  <td width="190" style="border:none;"></td>
  <td width="26" style="border:none;"></td>
  <td width="83" style="border:none;"></td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105442\07-16947-1\task2199075\16947-1-bc.htm',USER='105442',CD='Jun 19 21:18 2007' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>a07-16947_1ex99.htm
<DESCRIPTION>EX-99
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99</font></b></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 1 of 31</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN THE UNITED STATES DISTRICT COURT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR THE EASTERN DISTRICT OF TEXAS</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MARSHALL DIVISION</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RETRACTABLE TECHNOLOGIES, INC.,</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#167;</font></p>
  </td>
  <td width="47%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#167;</font></p>
  </td>
  <td width="47%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.58%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Plaintiff,</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#167;</font></p>
  </td>
  <td width="47%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CIVIL ACTION NO. 2:07-cv-250</font></p>
  </td>
 </tr>
 <tr>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#167;</font></p>
  </td>
  <td width="47%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(FOLSOM)</font></p>
  </td>
 </tr>
 <tr>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">v.</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#167;</font></p>
  </td>
  <td width="47%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#167;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" colspan="3" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BECTON DICKINSON AND COMPANY,</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#167;</font></p>
  </td>
  <td width="47%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.58%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#167;</font></p>
  </td>
  <td width="12%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:12.84%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="22%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.32%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">JURY TRIAL DEMANDED</font></p>
  </td>
  <td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.84%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.58%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Defendant.</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="12%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:12.84%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="22%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:22.32%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.84%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr height="0">
  <td width="160" style="border:none;"></td>
  <td width="191" style="border:none;"></td>
  <td width="45" style="border:none;"></td>
  <td width="50" style="border:none;"></td>
  <td width="46" style="border:none;"></td>
  <td width="167" style="border:none;"></td>
  <td width="39" style="border:none;"></td>
  <td width="50" style="border:none;"></td>
 </tr>
</table>

<p style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:none;text-transform:none;">&nbsp;</p>

<p style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:none;text-transform:none;">&nbsp;</p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">COMPLAINT</font></u></b></p>

<p style="font-size:10.0pt;font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:none;text-transform:uppercase;">&nbsp;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Plaintiff
Retractable Technologies, Inc. (&#147;Retractable&#148;) files this action complaining of
defendant Becton Dickinson and Company (&#147;BD&#148;), and for causes of action would
show as follows:</font></p>

<p align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">INTRODUCTION</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Defendant BD
has harmed Retractable and is continuing to harm Retractable by infringing
Retractable&#146;s patents for safety syringes. BD has also harmed Retractable and
the American public, and is continuing to harm Retractable and the American
public, by falsely advertising BD&#146;s inferior, non-infringing syringe products
as &#147;safe,&#148; &#147;safety,&#148; or &#147;safety engineered,&#148; in order to obtain time to switch
the market, at BD&#146;s own pace, to BD&#146;s infringing version of Retractable&#146;s
safety syringes, which BD calls &#147;Integra&#148; syringes. Finally, BD has harmed
Retractable and the American public, and is continuing to harm Retractable and
the American public by employing unlawful exclusionary schemes to keep Retractable&#146;s
technologically superior safety needle products from the market.</font></p>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>

<div align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 2 of 31</font></p>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Retractable
has chosen to file this action in this Honorable Court because venue is proper
in this forum and because this Court already has examined Retractable&#146;s
technology at issue and construed claims of two of the patents at issue in this
action (the &#147;011 Patent&#148; and the &#147;077 Patent&#148;). <i>See</i>
Memorandum Opinion in <i>Retractable Technologies
v. New Medical Technologies</i>, No. 4:02-CV-34 (LED). BD has copied and
infringed Retractable patented technology that this Court examined in <i>New Medical Technologies</i>.</font></p>

<p align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">NATURE
OF THIS ACTION</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Retractable&#146;s
patented safety syringe technology virtually eliminates the risk of needlestick
injuries to healthcare workers. Needlestick injuries can transmit to healthcare
workers potentially deadly diseases such as hepatitis B, hepatitis C and Human
Immunodeficiency Virus (&#147;HIV&#148;), the virus that causes AIDS. The American Nurses
Association estimates that more than 600,000 contaminated needlestick injuries
are reported each year in the United States. (<i>See</i></font>
</font>www.nursingworld.org/readroom/fsneedle.htm.)</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD is the nation&#146;s
dominant maker and seller of disposable syringes and other needle products. BD
is using a combination of intentional, unlawful methods, including patent
infringement, false advertising, unfair competition, and exclusionary
monopolistic behavior, to suppress Retractable&#146;s success in the market while BD
phases new products into the market that copy Retractable&#146;s technology and
infringe Retractable&#146;s patents. BD is now introducing its infringing new
products into the market at a controlled pace that enables BD to continue to
extract maximum profits from BD&#146;s existing, but obsolete and dangerous, needle
product technologies. By its unlawful conduct, BD has denied, and continues to
deny, American healthcare workers access to Retractable&#146;s products, which are
available now, and which incorporate the most innovative and effective safety
technology available.</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->


<br clear="all" style="page-break-before:always;">


<div>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 3 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Retractable files
this action seeking judicial relief to terminate BD&#146;s unlawful conduct. If
unchecked, BD will continue to infringe Retractable&#146;s patents, deceive the
market through false advertising about its own products, and engage in unfair
competition and unlawful monopolistic, exclusionary conduct. BD&#146;s conduct is
greatly and irreparably damaging Retractable and at the same time denying
American healthcare workers and patients the immediate benefits of Retractable&#146;s
superior safety needle products.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Retractable seeks
all relief the law allows for patent infringement. For Retractable&#146;s other
claims, Retractable seeks injunctive relief and damages accruing after July 2,
2004.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">PARTIES</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Plaintiff
Retractable is a Texas corporation with its principal place of business in
Little Elm, Texas, within the Eastern District of Texas. Retractable is a
publicly-traded company that employs approximately 150 persons within this
District.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Defendant BD is a
New Jersey corporation with its principal place of business in Franklin Lakes,
New Jersey. BD may be served with process in this action by serving its
registered agent for the service of process in the State of Texas, CT
Corporation System, 350 N. St. Paul St., Dallas, Texas&#160; 75201.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">JURISDICTION
AND VENUE</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This court has
subject matter jurisdiction under the patent laws set forth in Title 35 of the
United States Code and in Title 28 of the United States Code, particularly 28
U.S.C. &#167;&#167; 1331 and 1338(a); Section 43(a) of the Lanham Act, 15 U.S.C. &#167;
1125(a)(1)(B); the Sherman Act, 15 U.S.C. &#167;&#167; 1 <i>et
seq</i>.; Sections 3, 4 and 16 of the Clayton Act, 15 U.S.C. &#167;&#167; 14, 15
and 26; and 28 U.S.C. &#167;&#167; 1331 and 1337. This Court has supplemental
jurisdiction over Retractable&#146;s state law claims pursuant to 28 U.S.C. &#167; 1367
because they are so related to Retractable&#146;s federal</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 4 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">claims
as to form a part of the same case or controversy. In addition, this Court has
jurisdiction under 28 U.S.C. &#167; 1332(a) because this action is between citizens
of different states and the matter in controversy exceeds the sum or value of
$75,000, exclusive of interest and costs.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Court has
personal jurisdiction over BD. BD holds a certificate of authority to transact
business in Texas and regularly transacts business within Texas and the Eastern
District of Texas.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD has marketed and
continues to market its infringing &#147;Integra&#148; 1 cc and 3 cc syringes within
Texas and the Eastern District of Texas.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD&#146;s commercial
activities carried on in Texas and elsewhere throughout the United States have
had a substantial, direct and reasonably foreseeable effect on business and
commerce in the Eastern District of Texas and on interstate commerce.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Venue is proper in
this District under 28 U.S.C. &#167; 1391(b) and (c), 28 U.S.C. &#167; 1400(b), and 15
U.S.C. &#167; 22.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">BACKGROUND
FACTS</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h5 style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Retractable&#146;s Patented Safety Syringe.</font></b></h5>

<h5 style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h5>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Retractable markets
patented safety syringes under the name &#147;VanishPoint</font><font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>.&#148;&#160;
VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>&#160;syringes
are covered by a number of patents, including United States Patent Nos.
5,578,011, 5,632,733, and 6,090,077 (the &#145;011, &#145;733 and &#145;077 Patents), the
patents-in-suit. VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes protect against needlestick injuries.
VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes automatically and permanently
retract their needle after an injection is given and before the needle is
withdrawn from the patient. Consequently, VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes require no extra action by a
healthcare worker to trigger their safety feature after the needle is withdrawn
from a patient. Retractable and its VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>products have been reported favorably in
major news features, including in the <i>New
York Times</i> and on CBS&#146; <i>60
Minutes</i>.</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF &#160;&#160;&#160;Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 5 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; VanishPoint</font><font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>&#160;syringes have been recognized as superior
safety products. For one example, in 1999 and thereafter the Emergency Care
Research Institute (&#147;ECRI&#148;), a respected testing and evaluation service, has
awarded VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>&#160;syringes its highest rating and listed them as
preferred devices. (<i>HEALTH DEVICES</i>,
Sept. 2003, Vol. 32, No. 9, at p. 356.)</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h5 style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">BD&#146;s
Inferior Alleged &#147;Safety&#148; Syringes Render BD Competitively Vulnerable.</font></b></h5>

<h5 style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h5>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In contrast to
Retractable&#146;s superior safety products introduced in the mid to late 1990&#146;s, BD
lacked innovative technology in the field of safety syringes. At the same time,
the healthcare market demand for safety syringes was increasing dramatically. BD
understood its vulnerability to Retractable. In order to protect its position,
BD began to take unlawful actions to copy Retractable&#146;s patented technology,
prevent and suppress Retractable&#146;s sales, and defend, maintain and extend its
market dominance. Such unlawful actions by BD continue to the present day.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The legal
environment for needle products began to rapidly change in 1999. On July 1,
1999, California&#146;s Needle Safety Law became effective. The Texas act became
effective September 1, 1999. <i>See</i> TEX.
HEALTH &amp; SAFETY CODE &#167;&#167; 81.301, <i>et seq. </i>On
November 5, 1999, OSHA issued its Directive for Enforcement Procedures for the
Occupational Exposure to Bloodborne Pathogens. On November 6, 2001, the federal
Needlestick Safety and Prevention Act, P.L. 106-430 (&#147;Needlestick Prevention
Act&#148;) became law. The Needlestick Prevention Act requires healthcare employers
to track needlestick injuries and to involve healthcare workers in selecting
safer needle products. Since 1999, several other states also have enacted
statutes to prevent needlestick injuries to healthcare workers. Beginning in
2001, OSHA regulations codified at 29 C.F.R. &#167; 1910.1030 have required
hospitals and other medical facilities to track and report needlestick
incidents and to involve front line healthcare workers in annual reviews of
safety programs and needle devices. The OSHA regulations also require hospitals
to employ</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->


<br clear="all" style="page-break-before:always;">


<div>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 6 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;engineering
controls,&#148; defined to include &#147;self-sheathing needles and safer medical devices
such as sharps with engineered sharps injury protections,&#148; and to evaluate the
available needle products on the market and to select and use products that are
effective in preventing needlesticks.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As a result of these
statutes and growing awareness of the needlestick problem, the healthcare
industry needed and began to demand &#147;safety&#148; needle products.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Even though BD began
to market product lines of needle products as &#147;safe,&#148; &#147;safety,&#148; or &#147;safety-engineered,&#148;
those products were not safe. Rather, BD&#146;s first alleged &#147;safety&#148; products
incorporate nothing more than ineffective add-ons to BD&#146;s conventional
disposable syringe products. BD&#146;s first alleged &#147;safety&#148; products are no safer
than conventional syringes. In some ways, they are even more dangerous because
they require a nurse or other healthcare worker to place a second hand in
contact with the syringe after the needle is extracted from the patient to
activate the alleged &#147;safety&#148; feature.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD&#146;s first
generation alleged &#147;safety&#148; syringe was the &#147;Safety-Lok.&#148;&#160; The Safety-Lok contains an outer sleeve that
a user must slide over the needle after an injection is complete and the needle
is withdrawn from the patient. To operate this mechanism a user must use both
hands, one to hold the syringe and the other to slide the sleeve from its
position around the barrel to its extended position over the needle. This
places the user&#146;s free hand at an increased risk of contacting the exposed,
contaminated needle. BD&#146;s Safety-Lok mechanism is not automatic. It requires a
user to actively cover the needle of the syringe. If a user takes no action,
the needle remains exposed and the syringe is more bulky, harder to manipulate
and no safer than a conventional syringe. It also requires more space in a
sharps container, increasing costs and risks of disposal.</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->


<br clear="all" style="page-break-before:always;">


<div>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 7 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD&#146;s second
generation alleged &#147;safety&#148; syringe was the &#147;Safety Glide.&#148;&#160; The Safety Glide incorporates a small hinged
lever between the base of the needle and the pointed tip that, when pressed
forward, extends a cover over the needle tip. Activation can only occur after
the contaminated needle is removed from the patient. Like the Safety-Lok, a
nurse or doctor must, after injecting a patient, reach down to the syringe to
engage the lever. This action again places the user&#146;s hand in close proximity
to the contaminated needle, thereby increasing the risk of a needlestick injury.
Like the earlier Safety-Lok, BD&#146;s Safety Glide requires a user to take an
additional physical action to press the hinged lever before the safety device
engages. There have been reports that the safety feature on these earlier
generation BD products from time to time would simply fall off the syringe,
thereby exposing the contaminated needle. (<i>CBS
60 Minutes, </i>broadcast Feb. 25, 2001.<i>)</i></font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Another alleged &#147;safety&#148;
syringe marketed by BD is the &#147;Eclipse,&#148; which features a hinged shield at the
base of the needle that can be pivoted to cover the needle. After injecting a
patient, a user must withdraw the needle from the patient, reach down to the
exposed, contaminated needle, and flip the Eclipse shield into place by hand or
place the syringe with its exposed needle on a table-top or other firm surface
against which the shield can be flipped into place. Flipping the shield into
place also can throw blood or aerosolized medicine from the needle and onto
healthcare providers, patients, or surrounding surfaces.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As the healthcare
industry began to comply with the Needlestick Prevention Act, OSHA
requirements, and state needlestick safety laws, BD needed to accelerate the
conversion of its product line from conventional to safety syringes. At the
same time, BD began to take a series of actions to protect its dominant market
positions in needle products from Retractable&#146;s innovative, patented
technology.</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 8 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD was unable to
replace its inferior &#147;safety&#148; product line overnight. Nor did it want to do so
when it was reaping substantial profits from the stop-gap alleged &#147;safety&#148;
products that used parts from already-existing manufacturing facilities and
tools. Instead, BD, misusing its power in the markets, continued to market its
inferior alleged &#147;safety&#148; products.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">BD&#146;S
UNLAWFUL ACTS</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h5 style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Patent Infringement</font></b></h5>

<h5 style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h5>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon information and
belief, BD copied Retractable&#146;s syringes during the course of developing BD&#146;s
fourth generation of so-called &#147;safety&#148; syringe, the Integra. During a 2001
interview, the CEO of BD admitted that BD was not the first to invent many of
its products and that &#147;we&#146;re just good adapters.&#148; (Philip Siekman, <i>Becton Dickinson Takes a Plunge With Safer Needles;
By Gearing Up to Make Devices Like These the Company is Giving its Profits a
Shot in the Arm</i>, <i>FORTUNE</i>
(October 2001) at 2 (Lexis print).)</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Once BD had made a
syringe incorporating much of the technology disclosed in Retractable&#146;s
syringes and patents, BD unveiled the &#147;Integra&#148; syringe in 2003. Unlike BD&#146;s
earlier alleged &#147;safety&#148; syringes, Integra is a retractable syringe.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD&#146;s Integra
syringes infringe Retractable&#146;s patents. Like VanishPoint</font><font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes, Integra syringes have a spring loaded needle that is fired by
continuing to push the plunger after the injection is complete. This releases
the needle holder from a retaining ring so the needle retracts back into the
syringe body. The Integra syringes also use the same &#147;breakaway&#148; feature for
releasing the needle holder from the retainer ring that is taught in
Retractable&#146;s patents. The Integra 3 cc syringe has a plunger thumb cap that
tucks down into the top of the syringe barrel so that it cannot be easily
pulled out and reused, and has vents to relieve air pressure from the
retraction cavity and prevent splattering when the needle is retracted. These
features are disclosed and claimed in Retractable&#146;s patents.</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->


<br clear="all" style="page-break-before:always;">


<div>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 9 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As BD sells
infringing syringes and engages in other illegal activities, Retractable is
losing the value of its most valuable asset, which is the remaining term of its
patents. Retractable&#146;s patents are assets with definite expiration dates. Once
Retractable&#146;s patents expire, its lost opportunity in the marketplace cannot be
fully reclaimed.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD&#146;s infringement of
Retractable&#146;s patents, together with its unlawful exclusion of Retractable from
the markets, is greatly damaging both Retractable and healthcare workers. Through
BD&#146;s infringing manufacture and sale of its Integra products, BD can control
the demand for retractable syringes that occurs when healthcare workers are
made aware of the superior safety and ease of use of Retractable&#146;s patented
technology. BD can claim, in effect, &#147;Oh, we have one of those retractable
needles,&#148; while continuing to sell its older &#147;safety&#148; products on which BD
maintains substantially higher profit margins. In this way, BD can maintain
control of the entire market and use the Integra products as an aid to
extending its profits and sales of its earlier non-retractable &#147;safety&#148; syringe
products such as the Safety-Lok, the Safety Glide and the Eclipse. Hundreds of
thousands of needlestick injuries, each representing possible disease or death
to a healthcare worker, will continue to occur if BD&#146;s unlawful conduct
continues unchecked. BD&#146;s actions have caused and will continue to cause
irreparable harm to Retractable, medical personnel, and the general public.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h5 style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">False Advertising</font></b></h5>

<h5 style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h5>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BD&#146;s Safety&#150;Lok,
Safety Glide, and Eclipse products are no safer than, and can be less safe
than, conventional needle products. At least one study has shown that the
number of needlestick injuries decreased after a test group ceased using the
Safety-Lok syringe and resumed using conventional syringes. Nevertheless, BD
continues to advertise the Safety&#150;Lok, Safety Glide, and Eclipse products as &#147;safe,&#148;
&#147;safety,&#148; or &#147;safety-engineered&#148; products.</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-01.htm',USER='105348',CD='Jun 19 21:13 2007' -->



<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 10 of 31</font></p>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A recent study by an independent hospital
found that needlestick injuries increased when the hospital began to use BD&#146;s
alleged &#147;safety&#148; products in 2003. The same study showed that needlestick
injuries were virtually eliminated when the hospital switched to VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>&#160;products in 2004 and 2005.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Public records show that most current
so-called &#147;safety&#148; needles sold, most of which are the BD Safety-Lok, Safety
Glide and Eclipse needles described above, are ineffective. For example, in
2004 the State of Texas received reports of 370 needlestick incidents involving
so-called &#147;safety engineered&#148; products. In 243 of those incidents, the alleged &#147;safety
mechanism&#148; had not even been activated (www.state.tx.us/
idcu/health/bloodborne_pathogens /report/&#150; Tables 18 and 19). Accordingly, BD&#146;s
Safety-Lok, Safety Glide and Eclipse products are dangerous for the additional
reason that the alleged &#147;safety&#148; features on those products are feared or not
trusted by, and thus not activated by, the healthcare workers they purport to
protect.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Since on or about
July 2004, and continuing to the present, BD has in connection with its
Safety-Lok, Safety Glide, and Eclipse products, used in interstate commerce
words, terms, names, and combinations thereof, and false and misleading
descriptions and representations of fact, in commercial advertising and
promotion to misrepresent the nature, characteristics, and qualities of the
Safety-Lok, Safety Glide, and Eclipse products, all in violation of Section
43(a) of the Lanham Act, 15 U.S.C. &#167; 1125(a)(1)(B).</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s Safety-Lok is no safer, and indeed can
be more dangerous, than conventional syringes because the Safety-Lok contains
an outer sleeve that a user must physically push over the exposed needle after
an injection is complete. This action places the user&#146;s hand at increased risk
of contacting the contaminated needle. BD nevertheless uses the words, terms,
and names &#147;safe,&#148; &#147;safety,&#148; &#147;safety-engineered&#148; and similar descriptions in</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 11 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">commercial
advertising and promotion to describe the nature, characteristics, and
qualities of the Safety-Lok syringe, all in violation of Section 43(a) of the
Lanham Act, 15 U.S.C. &#167; 1125(a)(1)(B).</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s Safety Glide is no safer, and indeed can
be more dangerous, than conventional syringes because it has a small hinged
lever at the base of the needle that, when pressed by the user, extends a cover
over the needle. Consequently, after using the syringe to inject a patient and
withdrawing the needle from the patent, the user must reach down to the needle
and engage the lever. This action places the user&#146;s hand in close proximity to
the blood-contaminated needle, thereby increasing the risk of a needlestick
injury. BD nevertheless uses the words, terms, and names &#147;safe,&#148; &#147;safety,&#148; &#147;safety-engineered,&#148;
and similar descriptions in commercial advertising and promotion to describe
the nature, characteristics, and qualities of the Safety Glide syringe, all in
violation of Section 43(a) of the Lanham Act, 15 U.S.C. &#167;&nbsp;1125(a)(1)(B).</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s Eclipse products are no safer, and
indeed can be more dangerous, than conventional products because they include a
hinged shield at the base of the needle that when hit or pushed flips into
place over the needle. A user must, after injecting a patient and withdrawing
the needle from the patient, reach down to the needle with a hand to flip the
shield into place, or else move the syringe, with its exposed,
blood-contaminated needle exposed, to a table-top or other firm surface against
which the hinged shield can be flipped into place. Flipping the shield into
place has been observed to throw blood and/or aerosolized medicine from the
needle and onto healthcare providers, patients, or surrounding surfaces, thus,
increasing the risks of infection. BD nevertheless uses the words, terms, and
names &#147;safe,&#148; &#147;safety,&#148; &#147;safety-engineered&#148; and similar descriptions in commercial
advertising and promotion to</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 12 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">describe
the nature, characteristics and qualities of the Eclipse syringe, all in
violation of Section 43(a) of the Lanham Act, 15 U.S.C. &#167; 1125(a)(1)(B).</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This false advertising is damaging both
Retractable and the public and, in particular, healthcare workers. By promoting
the Safety-Lok, the Safety Glide and the Eclipse as &#147;safe&#148; when they are in
fact not, BD implies to healthcare workers and healthcare employers not only
that the products provide protection from needlestick injuries, but also, and
just as damaging, that purchase and use of such products will place the
healthcare entity in &#147;compliance&#148; with the provisions of the Needlestick
Prevention Act. Thus, the false advertising allows BD to sell its high profit
margin unsafe &#147;safety&#148; products and needles as a dodge around the intent of
Needlestick Prevention Act and thereby block adequate consideration of
Retractable&#146;s clearly safer technology.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h5 style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Antitrust Violations</font></b></h5>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; </font><u>Relevant Markets and BD&#146;s
Monopolies</u></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s conduct alleged in this Complaint
affects interstate trade and commerce. BD&#146;s annual revenues are measured in
billions of dollars, and BD&#146;s products are manufactured and sold throughout the
United States, including in Texas. BD&#146;s conduct was intended to maintain and
extend its market power in the nationwide markets for safety syringes and
needles and safety blood collection devices (&#147;Safety Needle Devices&#148;).</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>By way of background, in 1964 BD entered into
a consent judgment with the United States Department of Justice that prohibited
BD&#146;s continuation of monopolistic practices in the glass syringe market. That
judgment, which is technically still in force, specifically related to only <u>glass
syringes</u> even though BD was in the process of shifting its entire
manufacturing and the same illegal marketing practices to <u>plastic</u>
disposable syringes. Its &#147;Plastipak&#148; plastic</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 13 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">disposable
syringe was introduced in the 1960&#146;s and allowed BD to continue its
monopolistic practices with impunity.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For decades now, BD has maintained dominance
in the market for disposable syringes (conventional and safety), which replaced
glass syringes. In 2005 BD was estimated to control over 70% of the United
States market for syringes and needles. (&#147;U.S. Syringes and Needle Markets&#148;,
F876-54, 2-29, Frost &amp; Sullivan, 2006.)</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Additionally, BD has long enjoyed monopoly
power in the conventional (non-safety) injection and drug infusion market. Even
as the market for safety needle products has grown, conventional needle
products still possess a significant share of the overall market. A recent
study projected there will still be a 50-50 split of the market as late as
2012. (&#147;U.S. Syringes and Needle Markets&#148;, F876-54, 1-5, Frost &amp; Sullivan,
2006.)&#160;&#160; As a result, BD has a strong
economic incentive to keep Retractable out of the market for safety needle
products, not only so BD can maintain its prices for those products, but also
so it can maintain its monopoly in non-safety product lines.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Almost all needle products sold today are
marketed in both alleged &#147;safety&#148; and non-safety forms. Although safety and
non-safety products perform the same function, safety products should reduce
the risk of needlestick injury. The Needlestick Prevention Act has mandated use
of &#147;safer&#148; products. BD and other manufacturers are able to charge, and
healthcare workers are willing to pay, a higher price for Needle Products
marketed as &#147;safe,&#148; &#147;safety&#148; or &#147;safety-engineered&#148; products. As a consequence,
safety and non-safety versions of these products are today in separate product
sub-markets and have been since at least early 2004.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The relevant product markets impacted by BD&#146;s
antitrust violations are the nationwide markets for manufacture and
distribution of safety blood collection devices,</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 14 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(&#147;BCDs&#148;)
and safety syringes and needles (collectively, &#147;Safety Needle Devices&#148;). A
monopolist in these markets would be able to maintain the prices of Safety
Needle Devices above a competitive level without losing so many customers as to
make the maintenance unprofitable. Each of these products constitutes a
separate market with unique characteristics. BD&#146;s violations of the antitrust
laws have foreclosed and continue to foreclose Retractable from the market for
Safety Needle Devices.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Safety Needle Devices constitute a distinct
market from conventional needle devices. The relevant market for the
manufacture and distribution of Safety Needle Devices is a distinct market
because both suppliers and purchasers view Safety Needle Devices as distinct
products. Hospitals and healthcare workers distinguish between alleged safer
needle devices and their counterpart devices because of user preference for a
safer alternative and to avoid the costs involved in disease or death resulting
from needlestick injuries. Federal and state laws and regulations mandating use
of safer products also cause hospitals and healthcare workers to distinguish
between conventional needle products and Safety Needle Devices. Thus, end users
do not consider conventional needle products and Safety Needle Devices to be
substitutes for each other.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Furthermore, manufacturers of conventional
needle products cannot easily switch to manufacturing Safety Needle Devices
because the two products require different patents and capital equipment
including both molds and assembly equipment unique to each device. Safety
Needle Devices are significantly more complex products than conventional needle
products, incorporating additional moving parts and distinctive design
elements.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Safety syringes, and safety BCDs, each
constitute a distinct relevant market because each product cannot properly be
substituted for another for the same clinical use. A</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 15 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">nurse
cannot use a BCD to administer medication by injection, for example. End users
do not consider these Safety Needle Devices to be substitutes for one another. In
addition to these differences in product characteristics, the purchasers of
these products differ:&#160; BCDs are often
purchased for use in laboratories, while syringes are most often purchased by
hospitals or clinics. Manufacturers cannot easily switch from producing one
device, for example safety syringes, to another, such as safety BCDs, because
the devices require different patents, production lines, and regulatory
approvals. Further, there are substantial barriers to entry facing any
potential manufacturer of Safety Needle Devices. A potential entrant must have
a patent on its own technology or license to use someone else&#146;s technology. There
are high capital costs in designing and manufacturing a medical device. High
regulatory hurdles face all stages of manufacture and sale of medical devices.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In addition, Safety Needle Devices are also
sold in at least two separate customer markets. The acute care market, composed
of hospitals and related facilities that perform surgery on an in-patient
basis, and alternate care facilities that provide long-term nursing care, out
patient surgery, emergency care, physician services and the like, are
recognized sub-markets of the overall healthcare market. Even though the same
products may be marketed to both types of facilities, differences in volumes,
distribution, pricing and contracting mean that these are separate sub-markets.
BD controls both of these sub-markets with its overall monopoly power, and has
an especially tight grip on the acute care market.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>According to an independent study published
in 2006, reflecting data from 2005, BD has maintained monopoly power in the
market for all needle products. BD had over 71 percent of the total syringe and
needle market in 2005. BD had 88 percent of the BCD market in</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 16 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2005.
(&#147;U.S. Syringes and Needle Markets&#148;, F876-54, 2-29, 3-14, Frost &amp; Sullivan,
2006.)&#160; BD&#146;s market shares are greater
within the acute care sub-market.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The relevant geographic market for the
commerce at issue here is the United States. The United States has the
Needlestick Prevention Act that uniquely impacts the demand for Safety Needle
Devices. Patent laws and the regulatory conditions for sale of Safety Needle
Devices also vary from country to country, making the United States a distinct
geographic market.</h2>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; </font><u>BD&#146;s Unlawful Exclusionary
Tactics</u></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>From and after July 2, 2004, BD has continued
to employ various forms of exclusionary contracts with healthcare facilities in
order to frustrate, impair, and substantially foreclose competition from
Retractable and all other actual or potential manufacturers of Safety Needle
Devices. Under BD&#146;s exclusionary contracts, the prices that healthcare
facilities pay for BD&#146;s products are conditioned on the purchasers maintaining
BD&#146;s market share by agreeing to fill all, or nearly all, their Safety Needle
Device demand by purchasing BD products to the exclusion of competitive
products.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Under these exclusionary and anticompetitive
contracts, healthcare providers forfeit substantial BD rebates, as a penalty,
unless they purchase very high levels of their product needs from BD. Indeed,
under BD&#146;s contracts, if a healthcare entity were to fall even slightly below
BD&#146;s target level as the result of purchasing a competitor&#146;s needle products,
the healthcare entity would be penalized by: (a)&nbsp;becoming obligated to pay
higher prices for all or most BD products the entity purchases; (b)&nbsp;losing
post-purchase rebates for all or most BD products it</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 17 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">purchases;
and/or (c)&nbsp;in some circumstances becoming obligated to repay <i>past</i> rebates that the healthcare entity
received in connection with prior purchases of BD products</font><b>.</b></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s exclusionary penalty strategy works by
penalizing healthcare entities for purchasing products from BD&#146;s competitors. BD&#146;s
purchase requirements have the purpose and effect of denying market access to
Retractable and other potential and existing competitive manufacturers,
foreclosing and excluding them from the market.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD also maintains its market power by
unlawful bundling, or conditioning favored prices or rebates for products on a
healthcare entity&#146;s commitment to purchase BD products for most, if not all, of
the entity&#146;s needs in each of various product categories. For example, through
BD&#146;s bundling practices, a healthcare entity receives rebates for its purchases
of several types of BD products, but only if the healthcare entity satisfies BD&#146;s
requirements by buying a dominant amount of each of the different products in
BD&#146;s bundle.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Likewise, BD has bundled rebates and
discounts on its conventional needles with rebates and discounts on its alleged
&#147;safety&#148; needles. Thus, BD has been able to leverage its monopoly power in the
conventional needle products to impede and substantially foreclose competition
in the Safety Needle Devices relevant market. </h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Similarly, BD bundles rebates for its needle
products with unrelated healthcare products. Healthcare entities incur
penalties even if they purchase BD products for all of their needs in numerous
product categories, but buy even a small amount of only one or more of a
competitor&#146;s Safety Needle Products. The prospect of such a penalty creates
disincentives that makes it economically impractical or impossible for a
hospital to purchase a BD competitor&#146;s Safety Needle Products. BD&#146;s bundling
practices exclude and foreclose competition in markets in which BD has market
power and thereby unlawfully maintain BD&#146;s dominance.</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 18 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Many of BD&#146;s competitors in the Safety Needle
Device market are companies that concentrate in, manufacture and sell
specialized product lines. As a result, BD&#146;s penalty programs prevent
Retractable and other BD competitors from competing on price for their
specialized products by offering equal, offsetting discounts or price
reductions for those products. Even if a BD competitor substantially reduces
the price for its Safety Needle Devices, for example, that reduction will not
compensate the healthcare entity for the loss of discounts or rebates BD would
take away for other BD products in order to penalize the hospital from shifting
some or all of its Safety Needle Device purchases to the BD competitor. BD&#146;s
practices reward healthcare purchasers for purchasing BD&#146;s Safety Needle
Devices, in lieu of any other manufacturer&#146;s Safety Needle Devices, not because
BD&#146;s Safety Needle Devices are better or cheaper (which they are not), but in
order to retain greater discounts or concessions on products the other manufacturers
do not produce.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>After July 2,
2004, Retractable expanded its sales force and stepped up its efforts to market
VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes. To spur sales and increase market share,
Retractable reduced the price of VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes below those of other &#147;safety&#148; products then on the market. Even with
low prices nearly at conventional non-safety syringe levels, the hospitals did
not respond by purchasing VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes in greater volumes. Retractable&#146;s price reduction program, intended to
provide hospitals with a strong economic incentive to purchase VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes, was blocked by BD&#146;s exclusionary
contracts, BD&#146;s bundling practices, and other monopoly-protecting arrangements
BD had with hospitals that would have penalized the hospitals for purchasing VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringes.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In addition, 98 percent of American hospitals
are members of Group Purchasing Organizations (&#147;GPOs&#148;). GPOs offer most
products used in their member hospitals. Hospitals</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 19 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">join
GPOs through membership contracts that require member hospitals to do most or
all of their purchasing through the GPO. GPOs, in turn, enter into multi-year
contracts with manufacturers and suppliers of products used by hospitals. The
resulting list of GPO suppliers constitutes the &#147;approved&#148; list for purchases
by member hospitals. Upon information and belief, BD has entered into contracts
with GPOs that require the GPOs&#146; member hospitals to purchase high levels of
their Safety Needle Devices requirements from BD in order to maintain favorable
price discounts. In addition, on information and belief, BD enters into
so-called &#147;second event&#148; or &#147;aggregation&#148; contracts directly with hospitals and
hospital groups. These are exclusive dealing arrangements that provide for
additional &#147;discounts&#148; to hospitals and unless the hospitals agree to these
arrangements, they are penalized by having to pay higher prices for BD
products.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Thus, although Retractable has contracts with
several large GPOs and is therefore a qualified supplier to those GPOs&#146;
hospital members, in reality, purchases of Safety Needle Devices from
Retractable would subject hospitals to financial penalties in the forms of
reduced &#147;discounts&#148; or rebates from BD, even though the VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font><sup>&#160;</sup>syringe is the superior product and is priced competitively. BD also
contracts directly with hospitals and monitors its sales of a range of products
to those hospitals, penalizing the hospitals if they purchase goods, including
Retractable&#146;s Safety Needle Devices, that are not part of the contract.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">C.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; </font><u>BD Degrades Drug Delivery
Safety to Protect its Market Dominance</u></p>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has sacrificed patient safety by
designing, marketing, and promoting so-called &#147;needleless&#148; infusion syringe
systems designed to screw onto specially-made BD ports in drug delivery lines
attached to hospital patients. Either alone or in combination with other large
medical device manufacturers, BD redesigned disposable drug delivery systems
used in hospitals to deliver fluids and drugs to patients in a manner that
forecloses use of VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>&#160;syringes. The new infusion system requires a
new BD port (costing substantially more than the old ports)</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 20 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and
an intermediate connector piece that allows only a BD-manufactured syringe to
be screwed into the port for drug delivery.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s new infusion system guarantees use of BD&#146;s
&#147;needleless&#148; syringes for a large percentage of hospital usage and insures that
VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>&#160;syringes cannot be used to
deliver drugs in the hospital environment. But in order to deliver medications,
BD&#146;s alleged &#147;safety&#148; infusion syringe system requires procedures that increase
potential for contamination of a fluid line that is linked directly to the
patient&#146;s blood system. At least one hospital has reported that such &#147;open&#148;
systems increased infectious disease risk.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">60.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>On information and belief, BD knew or should
have known that its &#147;open&#148; infusion systems, while effective to maintain BD&#146;s
dominant market share, would needlessly increase infection risks to patients. Those
increased risks could have been avoided through use of a syringe designed with
a fully retracting needle to be used with a sealed, pierceable port. But BD did
not have a retractable syringe technology. To foreclose Retractable from this
significant segment of the hospital market, BD designed its new infusion system
to use only BD syringes and thereby placed patients at increased risk of
hospital-borne infections.</h2>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">D.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; </font><u>BD Suppresses Healthcare
Worker Knowledge of Retractable&#146;s Products</u></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Once nurses and hospital medical staff become
aware of Retractable&#146;s safety syringes, they often demand access to these
products. One analyst noted as recently as 2005: &#147;&#133;[E]nd users and distributors
are mostly unaware of the retractable-syringe technology.&#148; (&#147;Disposable Syringe
Markets&#148; p. 11, TriMark Publications, Sept. 2005.)</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has caused or induced potential customers
and trade shows to bar and exclude Retractable&#146;s sales staff from entering
premises or demonstrating the advantages of the VanishPoint<font size="1" face="Times New Roman" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>&#160;syringes. For example, Retractable has been
barred from one or more trade shows, even though the purpose of the shows was
to demonstrate available safety technology to medical</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 21 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">staff.
Hospital and trade show personnel have explained the exclusion of Retractable&#146;s
sales personnel by saying their facility is under contract with BD, exclusive
to BD, or standardized with BD.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">COUNT
1:&#160; INFRINGEMENT OF U.S. PATENT NO. 5,632,733</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All preceding paragraphs of this Complaint
are incorporated herein by reference as if fully set forth at length.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">64.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Plaintiff Retractable is the exclusive
licensee for, and has the right to sue in its own name on, United States Patent
No. 5,632,733 (&#147;the &#145;733 patent&#148;), issued May 27, 1997, a copy of which is
attached as Exhibit A. The maintenance fees for the &#145;733 patent have been
timely paid, and the &#145;733 patent has not been invalidated or found to be
unenforceable in any prior litigation.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At all times relevant to this action,
Retractable has complied with the notice provisions of 35 U.S.C. &#167; 287 as it
concerns the &#145;733 Patent.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">66.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has directly, indirectly, and/or
contributorily infringed the &#145;733 Patent by manufacturing, using, selling,
offering for sale and/or importing into the United States retractable syringes
covered by the &#145;733 Patent, and has induced and/or contributed to the
infringement of the &#145;733 Patent by others in the United States and within this
District, and will continue to do so unless enjoined by this Court.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No right or license to practice the invention
claimed in the &#145;733 patent has been granted to BD.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Retractable has been damaged by BD&#146;s
infringement and will be irreparably injured unless the infringement is
enjoined by this Court as provided by 35 U.S.C. &#167; 283.</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 22 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">COUNT 2:&#160; INFRINGEMENT OF U.S. PATENT NO. 6,090,077</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">69.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All preceding paragraphs of this Complaint
are incorporated herein by reference as if fully set forth at length.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">70.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Plaintiff Retractable is the exclusive
licensee for, and has the right to sue in its own name on, United States Patent
No. 6,090,077 (&#147;the &#145;077 patent&#148;), issued July 18, 2000, a copy of which is
attached as Exhibit B. The maintenance fees for the &#145;077 patent have been
timely paid, and the &#145;077 patent has not been invalidated or found to be unenforceable
in any prior litigation.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At all times relevant to this action,
Retractable has complied with the notice provisions of 35 U.S.C. &#167; 287 as it
concerns the &#145;077 Patent.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has directly, indirectly, and/or
contributorily infringed the &#145;077 Patent by manufacturing, using, selling,
offering for sale and/or importing into the United States retractable syringes
covered by the &#145;077 Patent, and has induced and/or contributed to the
infringement of the &#145;077 Patent by others in the United States and within this
District, and will continue to do so unless enjoined by this Court.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No right or license to practice the invention
claimed in the &#145;077 patent has been granted to BD.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Retractable has been damaged by BD&#146;s
infringement and will be irreparably injured unless the infringement is
enjoined by this Court as provided by 35 U.S.C. &#167; 283.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">COUNT
3:&#160; INFRINGEMENT OF U.S. PATENT NO.
5,578,011</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All preceding paragraphs of this Complaint
are incorporated herein by reference as if fully set forth at length.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">76.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Retractable is the exclusive licensee for,
and has the right to sue in its own name on, United States Patent No. 5,578,011
(&#147;the &#145;011 patent&#148;) issued November 26, 1995, a copy of</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 23 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">which
is attached as Exhibit C. The maintenance fees for the &#145;011 patent have been
timely paid, and the &#145;011 patent has not been invalidated or found to be
unenforceable in any prior litigation.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">77.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At all times relevant to this action,
Retractable has complied with the notice provisions of 35 U.S.C. &#167; 287 as it
concerns the &#145;011 Patent.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">78.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has directly, indirectly, and/or
contributorily infringed the &#145;011 Patent by manufacturing, using, selling,
offering for sale and/or importing into the United States retractable syringes
covered by the &#145;011 Patent, and has induced and/or contributed to the
infringement of the &#145;011 Patent by others in the United States and within this
District, and will continue to do so unless enjoined by this Court.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">79.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No right or license to practice the invention
claimed in the &#145;011 patent has been granted to BD.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">80.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Retractable has been damaged by BD&#146;s
infringement and will be irreparably injured unless the infringement is
enjoined by this Court as provided by 35 U.S.C. &#167; 283.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">WILLFUL
INFRINGEMENT</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">81.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s acts of infringement have been willful
and in deliberate disregard of the &#145;733, &#145;077 and &#145;011 Patents, and this is an
exceptional case under 35 U.S.C. &#167; 285.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">82.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has known that its non-infringing,
so-called &#147;safety&#148; syringes, which use add-on safety features, are not safe to
use in practice and that Retractable&#146;s patented retractable needle technology
had to be utilized in order to achieve a cost effective, manufacturable, safe
syringe. BD&#146;s failures in an attempt to use alternate technology are evidence
of the worth of Retractable&#146;s technology and BD&#146;s willful intent, namely, to
copy and use Retractable&#146;s technology for itself.</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\07-16947-1\task2198940\16947-1-mm-03.htm',USER='105344',CD='Jun 19 19:51 2007' -->



<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 24 of 31</font></p>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">83.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s infringing Integra syringe products are
promoted as being superior to VanishPoint<font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">&#174;</font>&#160;syringes, when, in fact, they are infringing
variants of the basic patented features of Retractable technology that deliver
safety and reliability to the healthcare worker.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">84.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD had full knowledge of, and has attempted
to obtain rights under, the patents-in-suit and decided to copy Retractable&#146;s
technology and use it to ward off growing demands for safer products in the
marketplace.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">COUNT
4:&#160; FALSE ADVERTISING IN VIOLATION <br>
OF SECTION 43(A) OF THE LANHAM ACT</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">85.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All preceding paragraphs of this Complaint
are incorporated herein by reference as if fully set forth at length.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">86.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has, in
connection with its Safety-Lok, Safety Glide, and Eclipse syringes, used in
interstate commerce words, terms, names, and combinations thereof, and false
and misleading descriptions and representations of fact, in commercial
advertising and promotion to misrepresent the nature, characteristics, and
qualities of the Safety-Lok, Safety Glide, and Eclipse syringes, all in
violation of Section 43(a) of the Lanham Act, 15 U.S.C. &#167; 1125(a)(1)(B).</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">87.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has
misleadingly and/or falsely used the words, terms, and names &#147;safe,&#148; &#147;safety,&#148;
or &#147;safety-engineered&#148; and various other similar descriptions in commercial
advertising and promotion to describe the nature, characteristics, and
qualities of the Safety-Lok, Safety Glide and Eclipse syringes, all in
violation of Section 43(a) of the Lanham Act, 15 U.S.C. &#167; 1125(a)(1)(B).</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">88.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The foregoing descriptions, representations, and
statements are illustrative, not
exhaustive, and were made in violation of Section 43(a) of the Lanham Act, 15
U.S.C. &#167; 1125(a)(1)(B).</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-05.htm',USER='105348',CD='Jun 19 21:11 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 25 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">89.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each of BD&#146;s false descriptions,
representations, statements, advertising, and promotions, described
herein or otherwise, has been intentional and willful, and has deceived or has
had the tendency to deceive a substantial portion of the intended audience in a
material manner, which has influenced or has had the likelihood to influence
purchasing decisions.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">90.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Moreover, BD&#146;s wrongful acts have caused, and
will continue to cause, Retractable to incur substantial damages, including,
but not limited to, declining sales, loss of goodwill, lost profits, and loss
of market share. Retractable therefore seeks recovery from BD of all amounts it
is entitled to under 15 U.S.C. &#167;&nbsp;1117(a), including, without
limitation:&#160; (1) BD&#146;s profits related to
its false and misleading descriptions, representations, statements, advertisements, and promotions; (2) all damages sustained by
Retractable; (3) the costs of this action; (4) treble damages, (5) reasonable
attorney fees; and (6) an additional amount that the Court considers just.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">91.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Retractable pleads for prospective injunctive
relief to enjoin BD&#146;s ongoing false and misleading descriptions,
representations, statements, advertisements, and promotions under 15
U.S.C. &#167; 1116(a).</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">92.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD has acted with unclean hands, and
Retractable&#146;s claims under Section 43(a) of the Lanham Act, 15 U.S.C. &#167;
1125(a)(1)(B), further the public interest.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">COUNT
5:&#160; VIOLATIONS OF THE SHERMAN AND CLAYTON
ACTS</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">93.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All preceding paragraphs of this Complaint
are incorporated herein by reference as if fully set forth at length.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">94.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The relevant geographic market is the United
States. As pleaded above, the relevant market segments for Safety Needle
Devices are acute care and alternate care medical facilities. The relevant
product markets for Safety Needle Devices are safety syringes and needles and
safety BCDs. BD has monopoly power in these relevant markets.</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-05.htm',USER='105348',CD='Jun 19 21:11 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 26 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">95.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Defendant BD has specifically intended, and
continues to intend, through its conduct alleged in this Complaint willfully to
maintain its monopoly power, control prices, exclude competitors, harm
consumers, and destroy competition in the relevant markets. Through the
activities alleged above, among others, BD has gained, maintained, extended,
and attempted to gain monopoly power in the acute care and alternate care
markets for Safety Needle Devices in violation of the Sherman Act, Section 2.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">96.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There is no legitimate business justification
for BD&#146;s exclusionary conduct.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">97.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As a direct and proximate result of Defendant
BD&#146;s unlawful actions alleged herein, Retractable has suffered injury to its
business and property. If BD&#146;s illegal conduct is not enjoined, Retractable
will suffer irreparable harm, and the markets for Safety Needle Devices will
remain distorted and substantially foreclosed to the detriment of consumers in
the market. Advances in Safety Needle Devices technology that could prevent
needlestick injuries and thereby prevent disease and save lives will continue
to be excluded from the market because BD exercises monopoly power to exclude
competitors and set prices.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">98.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Further, BD has made sales of Safety Needle
Devices and has set prices charged and discounts and rebates granted on those
sales based on the condition, agreement, or understanding that BD&#146;s buyer will
not purchase Retractable&#146;s products.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s exclusive dealing violates Section 3 of
the Clayton Act because it has foreclosed Retractable from substantial portions
of the markets for Safety Needle Devices and because it substantially lessens
competition in those markets and tends to maintain BD&#146;s monopoly power over
those markets.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s bundling practices also violate Section
2 of the Sherman Act and Section 3 of the Clayton Act because they exclude
Retractable and other BD competitors from substantial</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-05.htm',USER='105348',CD='Jun 19 21:11 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 27 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">portions
of the markets for Safety Needle Devices and because such practices
substantially lessen competition in those markets and tend to maintain BD&#146;s
monopoly over those markets.</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s willful taking of Retractable&#146;s
technology, resulting in the tort of patent infringement, constitutes an
illegal act that substantially lessens competition and tends to maintain BD&#146;s
dominance over the market for Safety Needle Devices.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">102.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s false advertising of its syringe and
blood collection tube products as &#147;safe,&#148; &#147;safety,&#148; &#147;safety-engineered&#148; and various
other similar descriptions in commercial advertising and promotion to describe
the nature, characteristics, and qualities of the Safety-Lok, Safety Glide and
Eclipse syringes constitute illegal acts that substantially lessen competition and tend to maintain BD&#146;s
dominance over the market for Safety Needle Devices.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">103.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>From and after July 2, 2004, Retractable has
been directly and proximately damaged by losses of sales and profits resulting
from BD&#146;s exclusive dealing, bundling arrangements, patent infringement, false
advertising and other monopolistic practices. Retractable seeks damages, treble
damages, and all other relief available to it under the antitrust laws. Retractable
will be irreparably harmed if BD&#146;s exclusive dealing and bundling arrangements,
patent infringement and false advertising are not enjoined.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">104.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Alternatively, Defendant BD has specifically
intended, and continues to intend, for its conduct alleged in this Complaint to
control prices, exclude competitors, and destroy competition in the relevant
markets for Safety Needle Devices. Through the activities alleged in the paragraphs
above, among others, BD has attempted to gain monopoly power in the markets for
Safety Needle Devices. BD&#146;s predatory and anticompetitive conduct presents a
dangerous probability that BD will succeed in monopolizing the Safety Needle
Devices markets because BD already has market power in those markets, which
contain high barriers to entry in the form</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-05.htm',USER='105348',CD='Jun 19 21:11 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 28 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of
capital costs, intellectual property requirements and costs, and other burdens.
As a direct and proximate result of BD&#146;s anticompetitive conduct alleged
herein, RTI has been injured in its business and property and suffered
substantial lost profits, and will suffer irreparable harm if BD is not
enjoined from continuing its illegal course of conduct.</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">COUNT
6:&#160; TEXAS ANTITRUST ACT</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">105.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All preceding paragraphs of the Complaint are
incorporated herein by reference as if fully set forth at length.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s conduct outlined in the federal
antitrust violations detailed above also violates the Texas Free Enterprise and
Antitrust Act of 1983, Tex. Bus. &amp; Com. Code Ann. &#167; 15.01 <i>et seq.</i> (Vernon 2003). Retractable seeks
an injunction, an award of damages, treble damages, recovery of its attorneys&#146;
fees, and all other relief available under said Texas Act. If BD&#146;s illegal
conduct alleged herein is not enjoined, Retractable will be irreparably damaged
and Texas markets for Safety Needle Devices will be substantially foreclosed to
competition.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">COUNT
7:&#160; UNFAIR COMPETITION</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">107.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All preceding paragraphs of this Complaint
are incorporated herein by reference as if fully set forth at length.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">108.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s tortious conduct alleged above in this
Complaint constitutes unfair competition in violation of the common law. BD and
Retractable are competitors. BD has unfairly competed with and sought to
destroy Retractable&#146;s business.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">109.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s conduct has damaged Retractable.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">INJUNCTIVE
RELIEF</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">110.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All preceding paragraphs of this Complaint
are incorporated herein by reference as if fully set forth at length.</h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-05.htm',USER='105348',CD='Jun 19 21:11 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 29 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">111.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Retractable is entitled to a permanent
injunction preventing BD from continuing to infringe the &#145;077, &#145;733, and &#145;011
Patents.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">112.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Retractable is entitled to a permanent
injunction preventing BD from continuing to advertise its Safety-Lok,
Safety Glide, and Eclipse syringes, using false and misleading descriptions and
representations of fact, such as &#147;safe,&#148; &#147;safety,&#148; and &#147;safety-engineered.&#148;</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Retractable is entitled to a permanent
injunction enjoining BD from continuing actively to exclude Retractable from
the markets described herein, and requiring BD to take corrective action to
remedy distortions in said markets caused by BD&#146;s continuing violations of the
federal and Texas antitrust laws. Injunctive relief would greatly serve the
public interest because the public has an interest in competitive markets and because
Retractable&#146;s products could be preventing needlestick injuries and thereby
preventing disease and death.</h2>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 style="font-size:10.0pt;font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">114.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD&#146;s violations of federal and Texas law are
continuing, and BD has demonstrated that it will continue in all of the conduct
described herein unless enjoined. Retractable is threatened with irreparable
harm from these continuing and future violations.</h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">PRAYER
FOR RELIEF</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<p style="margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREFORE,
PREMISES CONSIDERED, Plaintiff Retractable Technologies, Inc. prays that
Defendant Becton Dickinson and Company will be cited to appear and answer
herein and for Judgment of this Honorable Court as follows:</font></p>

<p style="margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD be adjudged and
decreed to have directly, indirectly, and/or contributorily infringed the &#145;733
Patent, the &#145;011 Patent, and the &#145;077 Patent;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD be adjudged and
decreed to have willfully and deliberately infringed the &#145;733 Patent, the &#145;011
Patent, and the &#145;077 Patent;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BD be ordered to pay
actual damages to Retractable, but not less than a reasonable royalty, by
reason of BD&#146;s infringement of the &#145;733 Patent, the &#145;011 Patent, and the</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-05.htm',USER='105348',CD='Jun 19 21:11 2007' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 30 of 31</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#145;077 Patent together with prejudgment
interest, costs and increased damages pursuant to 35 U.S.C. &#167; 284;</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A permanent injunction
be entered against BD, and its officers, agents, servants and employees, and
all entities and individuals acting in concert with them, to permanently
restrain any further infringement of the &#145;733 Patent, the &#145;011 Patent, and the &#145;077
Patent;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This case be declared
an &#147;exceptional case&#148; within the meaning of 35 U.S.C. &#167;285 and reasonable
attorneys&#146; fees, costs and treble damages be awarded to Retractable;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Enjoining BD from
continuing the anticompetitive conduct alleged in this Complaint;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Ordering BD to take
corrective steps to end the foreclosure of the relevant market and create a
competitive market for safer alternatives to conventional needles, syringes,
and blood collection devices and to remedy the market distortions created by
its past and continuing violations of the United States antitrust laws;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Awarding Retractable
treble damages resulting from BD&#146;s antitrust violations;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Awarding
Retractable (i) BD&#146;s profits, (ii) Retractable&#146;s damages, and (iii) costs of
the action, pursuant to 15 U.S.C. &#167; 1117(a);</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Awarding
Retractable all reasonable attorneys&#146; fees allowed by statute, expert fees,
costs, pre-judgment interest, and post-judgment interest; and</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Granting all such
other relief, at law and in equity, to which Retractable is entitled.</p>

<p align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">JURY
DEMAND</font></b></h1>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></h1>

<h2 style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:justify;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Retractable demands a trial by jury as is its right under the Seventh
Amendment to the Constitution of the United States or as given by statute. FED.
R. CIV. P. 38.</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></h2>

<h2 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="3" width="100%" noshade color="#010101" align="left">

</font></h2>

</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-05.htm',USER='105348',CD='Jun 19 21:11 2007' -->


<br clear="all" style="page-break-before:always;">


<div>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<p align="center" style="line-height:normal;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">Case
2:07-cv-00250-DF&#160;&#160;&#160; Document 1-1&#160;&#160;&#160; Filed 06/15/2007&#160;&#160;&#160; Page 31 of 31</font></p>

<h2 align="center" style="font-weight:normal;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></h2>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt 50.0pt;text-autospace:none;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated: June 15, 2007</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Respectfully
  submitted,</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Roy W.
  Hardin (with permission by Otis Carroll</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Roy W.
  Hardin</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-autospace:none;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Texas Bar No. 08968300</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">George E.
  Bowles</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-autospace:none;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Texas Bar No. 02743300</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael V.
  Powell</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-autospace:none;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Texas Bar No. 16204400</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Brad Weber</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-autospace:none;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Texas Bar No. 21042470</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul
  Schuster</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-autospace:none;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Texas Bar No.00784931</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stephen D.
  Wilson</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-autospace:none;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Texas Bar No. 24003187</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LOCKE
  LIDDELL &amp; SAPP LLP</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2200 Ross
  Avenue, Suite 2200</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dallas,
  Texas 75201-6776</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:
  (214) 740-8000</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:
  (214) 740-8800</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E-mail: <u>rhardin@lockeliddell.com</u></font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Otis Carroll</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">State Bar No. 03895700</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deborah Race</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">State Bar No. 16448700</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ireland, Carroll &amp; Kelley, PC</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6101 S. Broadway, Suite 500</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tyler, Texas 75703</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel. (903) 561-1600</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax (903) 581-1071</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Email: Fedserv@icklaw.com</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATTORNEYS FOR PLAINTIFF</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.92%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RETRACTABLE TECHNOLOGIES, INC.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31</font></p>

<div style="margin:0in 0in .0001pt;text-indent:0in;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\kgiri\07-16947-1\task2199076\16947-1-mm-05.htm',USER='105348',CD='Jun 19 21:11 2007' -->


</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
